CGEM

CGEM

USD

Cullinan Therapeutics Inc. Common Stock

$7.400-0.400 (-5.128%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$7.800

Máximo

$7.800

Mínimo

$7.360

Volume

0.61M

Fundamentos da empresa

Capitalização de mercado

437.2M

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

0.89M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $5.68Atual $7.400Máximo $17.503

Notícias relacionadas

GlobeNewswire

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate observed at clinically

Ver mais
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
GlobeNewswire

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage

Ver mais
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.